The objective is to formulate clinical practice guidelines for treating Cushing's syndrome.
Containing relevant Learning Zones, guidelines, trials and news.
Classical pituitary apoplexy is a medical emergency and rapid replacement with hydrocortisone maybe life saving. It is caused by haemorrhage and/or infarction of a tumour within the pituitary gland.
Xeris Biopharma announced the FDA approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative.
Recodati's inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people...
Recodati‘s inhibitor of cortisol synthesis, Isturisa (osilodrostat), has been approved by the European Commission (EC) for the treatment of people with endogenous Cushing’s syndrome, the company announced. The decision follows a European Medicines Agency (EMA) committee recommendation in November to approve Isturisa for that purpose.
Corcept Therapeutics Incorporated announced that GRACE, the Phase III trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpoint
The purpose of the guidelines is to encourage the widespread adoption of harmonized good practice in the diagnosis and management of patients with pituitary apoplexy.
This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.
Clobetasol propionate is a very potent topical corticosteroid which is indicated for use in short courses for conditions which do not respond satisfactorily to less active steroids. It is indicated for use in steroid responsive dermatoses of the scalp such as: - Psoriasis - Recalcitrant dermatoses.